TRYPHAENA

NCT00976989 📎

Regimen

Experimental
Three arms: (A) FEC + HP x3 then docetaxel + HP x3; (B) FEC x3 then docetaxel + HP x3; (C) TCHP x6 (anthracycline-free, carboplatin + docetaxel + trastuzumab + pertuzumab).
Control
No dedicated control; safety comparison across three HP-containing regimens.

Population

HER2-positive operable, locally advanced or inflammatory breast cancer >= 2 cm.

Key finding

TRYPHAENA established cardiac safety and pCR rates for TCHP (the anthracycline-free dual HER2 blockade backbone). Provided the safety rationale that made TCHP the default neoadjuvant regimen for HER2+ disease at most centers.

Source: PMID 23704196

Timeline

  • Publication: 2013 Sep

Guideline citations

  • NCCN BREAST